"Metabolic disruption technology holds tremendous hope for patients with drug resistant tumors," said Haig Keledjian, CEO of Viral Genetics. "Dr. Trauger has worked in the biotech industry for 20 years and for the last 15 years has focused exclusively on bringing new cancer therapies to the clinic. We believe that he has the knowledge and experience to take this program forward. Creating a new corporation dedicated to that effort is critical to give this science the attention it deserves. At the same time, it enables Viral Genetics to remain focused on its core mission of pursuing treatments for autoimmune diseases, in addition to our primary focus of HIV and AIDS."
Viral Genetics has an option to acquire exclusive rights to the metabolic disruption technology from the University of Vermont and the University of Colorado, where the technology was invented and developed by Dr. Newell. Viral Genetics is completing negotiations to convert the option into an exclusive worldwide license covering a broad range of uses and specific therapeutic compositions.
Upon completion of certain benchmarks, Dr. Trauger will have the opportunity to acquire a 25% stake in the new company.
Viral Genetics has taken additional steps to strengthen its place in the marketplace by filing an unaudited financial statement at www.PinkSheets.com. That statement covers the company's financials for the last 18-months through March 31, 2009. Viral Genetics also recently retired a significant portion of its debt, enabling the majority of any new funding to go directly to bringing new drugs to the marketplace.
ABOUT VIRAL GENETICS:
Headquartered in San Marino, California, Viral Genetics discovers and develops
|SOURCE Viral Genetics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved